multiple myeloma
Conditions
Brief summary
The number of patients with positive Fluciclovine PET/CT and negative FDG PET/CT and how this correlate to PFS and OS
Detailed description
The number of patients with positive Fluciclovine PET/CT and positive FDG PET/CT and how this correlate to PFS and OS, The number of patients with negative Fluciclovine PET/CT and positive FDG PET/CT and how this correlate to PFS and OS, The number of patients with negative Fluciclovine PET/CT and negative FDG PET/CT and how this correlate to PFS and OS, Evaluate the safety of Fluciclovine, by incidence and severity of AEs, Determine the agreement between Fluciclovine PET/CT and FDG PET/CT assessments
Interventions
Sponsors
Oslo University Hospital HF
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of patients with positive Fluciclovine PET/CT and negative FDG PET/CT and how this correlate to PFS and OS | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of patients with positive Fluciclovine PET/CT and positive FDG PET/CT and how this correlate to PFS and OS, The number of patients with negative Fluciclovine PET/CT and positive FDG PET/CT and how this correlate to PFS and OS, The number of patients with negative Fluciclovine PET/CT and negative FDG PET/CT and how this correlate to PFS and OS, Evaluate the safety of Fluciclovine, by incidence and severity of AEs, Determine the agreement between Fluciclovine PET/CT and FDG PET/CT assessments | — |
Countries
Norway
Outcome results
None listed